Эффективность неплатиновой монохимиотерапии в лечении платинорезистентных рецидивов рака яичников: мета‑анализ

Актуальность: Ключевую роль в лечении рецидивов РЯ играет правильное планирование стратегии лечения с последовательным назначением наиболее эффективных терапевтических опций. Неплатиновая химиотерапия может быть единственным вариантом лечения для пациенток с непереносимостью платины или платино-рефрактерным течением заболевания. Нами проведен мета-анализ, посвященный сравнению эффективности различных вариантов неплатиновой химиотерапии в лечении ранних рецидивов РЯ.

Материалы и методы: Был произведен поиск исследований в базе данных PubMed (с 01.01.2000 по 01.07.2019 гг.). Критерии отбора включали: 1) рецидивы эпителиального рака яичников, 2) бесплатиновый интервал ≤ 6 мес., 3) стандартная химиотерапия без включения таргетных, экспериментальных препаратов, высокодозной химиотерапии, 4) опубликованная частота объективного ответа и критерии оценки. Первичной конечной точкой анализа была частота объективного ответа (ЧОО). Статистический анализ данных был проведен методом мета-анализа (модель случайных эффектов) с использованием пропорций и бета-регрессионного анализа с помощью программного обеспечения R и RStudio (пакеты meta и betareg).

Результаты: Проанализировано 7156 исследований, для дальнейшего анализа было отобрано 157 исследований, соответствующих критериям включения, из них эффективность платиновой и неплатиновой химиотерапии была оценена в 44 (n = 1055) и 113 (n = 5272) исследованиях соответственно, в данный анализ включены работы с неплатиновой химиотерапией. По результатам мета-анализа показатель ЧОО в группе монотерапии таксанами, этопозидом, доксорубицином/ПЛД, топотеканом и гемцитабином составил 27 % (95 % ДИ 0,21–0,34), 19 % (95 % ДИ 0,13–0,27), 15 % (95 % ДИ 0,11–0,19), 13 % (95 % ДИ 0,10–0,18) и 10 % (95 % ДИ 0,07–0,14), соответственно. Бета-регрессионный анализ, проведенный с учетом количества линий предшествующей терапии, метода оценки эффекта и других факторов продемонстрировал схожие результаты.

Выводы: Монотерапия таксанами может быть наиболее эффективной неплатиновой химиотерапевтической опцией для пациентов, не являющихся кандидатами для назначения препаратов платины.

1. Каприн АД, Старинский ВВ, Шахзадова АО. Злокачественные новообразования в России в 2019 году: заболеваемость и смертность году – М.: МНИОМ им. П. А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020. – илл. – 252 с. ISBN 978-5-85502‑260-5.

2. Тюляндина АС, Коломиец ЛА, Морхов КЮ, et al. Практические рекомендации по лекарственному лечению рака яичников, первичного рака брюшины и рака маточных труб. Злокачественные Опухоли. 2021;11 (3s2):158-171.

3. Электронный ресурс: NCCN Clinical practice guidelines-Ovarian cancer, 2022. Последний доступ: 01.02.2022. Доступно онлайн на веб-странице: https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf.

4. Therasse P, Arbuck SG, Eisenhauer EA, et al. New Guidelines to Evaluate the Response to Treatment in Solid Tumors. J Natl Cancer Inst. 2000;92 (3):12.

5. Schwartz LH, Litière S, de Vries E, et al. RECIST 1.1—Update and clarification: From the RECIST committee. Eur J Cancer. 2016;62:132‑137. doi:10.1016/j.ejca.2016.03.081

6. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47 (1):207‑214. doi:10.1002/1097‑0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2‑6

7. Rustin GJS, Timmers P, Nelstrop A, et al. Comparison of CA‑125 and Standard Definitions of Progression of Ovarian Cancer in the Intergroup Trial of Cisplatin and Paclitaxel Versus Cisplatin and Cyclophosphamide. J Clin Oncol. 2006;24 (1):45-51. doi:10.1200/JCO.2005.01.2757

8. Rustin GJS, Vergote I, Eisenhauer E, et al. Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011;21 (2):419‑ 423. doi:10.1097/IGC.0b013e3182070f17

9. Safra T, Ron I, Boaz M, et al. Heavily pretreated ovarian cancer patients treated by single‑ agent gemcitabine. A retrospective outcome comparison between platinum‑sensitive and platinum‑resistant patients. Acta Oncol. 2006;45 (4):463-468. doi:10.1080/02841860500509035

10. Chanpanitkitchot S, Tangjitgamol S, Khunnarong J, Thavaramara T, Pataradool K, Srijaipracharoen S. Treatment Outcomes of Gemcitabine in Refractory or Recurrent Epithelial Ovarian Cancer Patients. Asian Pac J Cancer Prev. 2014;15 (13):5215-5221. doi:10.7314/APJCP.2014.15.13.5215

11. Kurzeder C, Bover I, Marmé F, et al. Double‑Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNAExpressing Platinum‑Resistant Ovarian Cancer (PENELOPE). J Clin Oncol. 2016;34 (21):2516-2525. doi:10.1200/JCO.2015.66.0787

12. Yoshino K, Hiramatsu K, Enomoto T, et al. Salvage Chemotherapy Using Gemcitabine for Taxane/ Platinum‑resistant Recurrent Ovarian Cancer: A Single Institutional Experience. ANTICANCER Res. Published online 2012:5.

13. Gonzalez BO, Martin AG, Barcelo IB, et al. A Phase II Trial of Fixed‑Dosed Rate Gemcitabine in Platinum‑Resistant Ovarian Cancer: A GEICO (Grupo Español de Investigación en Cáncer de Ovario) Trial. Am J Clin Oncol. 2008;31 (5):481‑ 487. doi:10.1097/COC.0b013e31816d1c7b

14. D’Agostino G, Ferrandina G, Ludovisi M, et al. Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer. Br J Cancer. 2003;89 (7):1180-1184. doi:10.1038/sj.bjc.6601284

15. Markman M, Webster K, Zanotti K, Kulp B, Peterson G, Belinson J. Phase 2 trial of single‑agent gemcitabine in platinum‑paclitaxel refractory ovarian cancer. Gynecol Oncol. 2003;90 (3):593-596. doi:10.1016/S0090-8258(03)00399‑8

16. Prasad M, Ben‑Porat L, Hoppe B, et al. Costs of treatment and outcomes associated with second‑line therapy and greater for relapsed ovarian cancer. Gynecol Oncol. 2004;93 (1):223-228. doi:10.1016/j.ygyno.2004.01.014

17. Makhija S, Amler LC, Glenn D, et al. Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum‑Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer. J Clin Oncol. 2010;28 (7):1215-1223. doi:10.1200/JCO.2009.22.3354

18. Takei Y, Takahashi Y, Machida S, et al. Response to and toxicity of gemcitabine for recurrent ovarian cancer according to number of previous chemotherapy regimens: GEM and number of previous regimens. J Obstet Gynaecol Res. 2017;43 (2):358-364. doi:10.1111/jog.13203

19. Suprasert P, Cheewakriangkrai C, Manopunya M. Outcome of Single Agent Generic Gemcitabine in Platinum‑Resistant Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Adenocarcinoma. Asian Pac J Cancer Prev. 2012;13 (2):517‑520. doi:10.7314/APJCP.2012.13.2.517

20. Mutch DG, Orlando M, Goss T, et al. Randomized Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Patients With Platinum‑Resistant Ovarian Cancer. J Clin Oncol. 2007;25 (19):2811‑2818. doi:10.1200/JCO.2006.09.6735

21. Ichikawa R, Torii Y, Oe S, et al. Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum‑resistant or-refractory epithelial ovarian and primary peritoneal carcinoma. Arch Gynecol Obstet. 2014;290 (5):979‑984. doi:10.1007/s00404-014-3268-7

22. Wilailak S, Linasmita V. A Study of Pegylated Liposomal Doxorubicin in Platinum‑Refractory Epithelial Ovarian Cancer. Oncology. 2004;67 (3-4):183-186. doi:10.1159/000081315

23. Gorumlu G, Kucukzeybek Y, Kemal‑ Gul M, et al. Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients.:4.

24. Dear RF, Gao B, Harnett P. Recurrent ovarian cancer: Treatment with pegylated liposomal doxorubicin; a Westmead Cancer Care Centre experience. Asia Pac J Clin Oncol. 2010;6 (1):66-73. doi:10.1111/j.1743-7563.2009.01263.x

25. Chou HH, Wang KL, Chen CA, et al. Pegylated liposomal doxorubicin (Lipo-Dox®) for platinum‑resistant or refractory epithelial ovarian carcinoma: A Taiwanese gynecologic oncology group study with long‑term follow‑up. Gynecol Oncol. 2006;101 (3):423-428. doi:10.1016/j.ygyno.2005.10.027

26. Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J. Phase 2 Trial of Liposomal Doxorubicin (40 mg/m2 ) in Platinum/Paclitaxel‑Refractory Ovarian and Fallopian Tube Cancers and Primary Carcinoma of the Peritoneum. Gynecol Oncol. 2000;78 (3):369‑372. doi:10.1006/gyno.2000.5921

27. Strauss HG, Hemsen A, Karbe I, Lautenschläger C, Persing M, Thomssen C. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum‑refractory ovarian and peritoneal cancer: Anticancer Drugs. 2008;19 (5):541‑545. doi:10.1097/CAD.0b013e3282fcbbf7

28. Campos SM, Penson RT, Mays AR, et al. The Clinical Utility of Liposomal Doxorubicin in Recurrent Ovarian Cancer. Gynecol Oncol. 2001;81 (2):206-212. doi:10.1006/gyno.2000.5980

29. Naumann RW, Coleman RL, Burger RA, et al. PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum‑Resistant Ovarian Cancer. J Clin Oncol. 2013;31 (35):4400-4406. doi:10.1200/JCO.2013.49.7685

30. Vergote I, Finkler NJ, Hall JB, et al. Randomized Phase III Study of Canfosfamide in Combination With Pegylated Liposomal Doxorubicin Compared With Pegylated Liposomal Doxorubicin Alone in Platinum‑Resistant Ovarian Cancer. Int J Gynecol Cancer. 2010;20 (5):772‑780. doi:10.1111/IGC.0b013e3181daaf59

31. Pujade‑Lauraine E, Hilpert F, Weber B, et al. Bevacizumab Combined With Chemotherapy for Platinum‑Resistant Recurrent Ovarian Cancer: The AURELIA Open‑Label Randomized Phase III Trial. J Clin Oncol. 2014;32 (13):13021308. doi:10.1200/JCO.2013.51.4489

32. Adams SF, Marsh EB, Elmasri W, et al. A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer. Gynecol Oncol. 2011;123 (3):486-491. doi:10.1016/j.ygyno.2011.08.032

33. Rose PG, Hawthorne Maxson J, Fusco N, Mossbruger K, Rodriguez M. Liposomal Doxorubicin in Ovarian, Peritoneal, and Tubal Carcinoma: A Retrospective Comparative Study of Single‑Agent Dosages. Gynecol Oncol. 2001;82 (2):323-328. doi:10.1006/gyno.2001.6272

34. Steppan I, Reimer D, Sevelda U, Ulmer H, Marth C, Zeimet AG. Treatment of Recurrent Platinum‑Resistant Ovarian Cancer with Pegylated Liposomal Doxorubicin – An Evaluation of the Therapeutic Index with Special Emphasis on Cardiac Toxicity. Chemotherapy. 2009;55 (6):391‑398. doi:10.1159/000262452

35. Gordon AN, Granai CO, Rose PG, et al. Phase II Study of Liposomal Doxorubicin in Platinum‑ and Paclitaxel‑Refractory Epithelial Ovarian Cancer. J Clin Oncol. 2000;18 (17):3093-3100. doi:10.1200/JCO.2000.18.17.3093

36. Hensley ML, Hoppe B, Leon L, et al. The Costs and Efficacy of Liposomal Doxorubicin in Platinum‑Refractory Ovarian Cancer in Heavily Pretreated Patients. Gynecol Oncol. 2001;82 (3):464-469. doi:10.1006/gyno.2001.6299

37. Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer. J Clin Oncol. 2010;28 (19):3107‑3114. doi:10.1200/JCO.2009.25.4037

38. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan. J Clin Oncol. 2001;19 (14):33123322. doi:10.1200/JCO.2001.19.14.3312

39. Colombo N, Kutarska E, Dimopoulos M, et al. Randomized, Open‑Label, Phase III Study Comparing Patupilone (EPO906) With Pegylated Liposomal Doxorubicin in Platinum‑Refractory or-Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal Cancer. J Clin Oncol. 2012;30 (31):3841‑3847. doi:10.1200/JCO.2011.38.8082

40. Alici S, Saip P, Eralp Y, Aydiner A, Topuz E. Oral Etoposide (VP16) in Platinum‑Resistant Epithelial Ovarian Cancer (EOC): Am J Clin Oncol. 2003;26 (4):358-362. doi:10.1097/01.COC.0000020590.62677.E0

41. Kucukoner M, Isikdogan A, Yaman S, et al. Oral Etoposide for Platinum‑Resistant and Recurrent Epithelial Ovarian Cancer: a Study by the Anatolian Society of Medical Oncology. Asian Pac J Cancer Prev. 2012;13 (8):3973-3976. doi:10.7314/APJCP.2012.13.8.3973

42. Bozkaya Y, Doğan M, Umut Erdem G, et al. Effectiveness of low‑ dose oral etoposide treatment in patients with recurrent and platinum‑resistant epithelial ovarian cancer. J Obstet Gynaecol. 2017;37 (5):649‑ 654. doi:10.1080/01443615.2017.1290056

43. Elkas JC, Holschneider CH, Katz B, et al. The use of continuous infusion topotecan in persistent and recurrent ovarian cancer. Int J Gynecol Cancer. 2003;13 (2):138-141. doi:10.1046/j.1525-1438.2003.13020.x

44. Denschlag D, Watermann D, Hörig K, Kissel C, Tempfer C, Gitsch G. Topotecan as a Continuous Infusion Over 14 Days in Recurrent Ovarian Cancer Patients.:3.

45. Kakolyris S, Kouroussis Ch, Souglakos J, et al. A Phase I Clinical Trial of Topotecan Given Every 2 Weeks in Patients with Refractory Solid Tumors. Oncology. 2001;61 (4):265-270. doi:10.1159/000055332

46. Levy T, Inbar M, Menczer J, Grisaru D, Glezerman M, Safra T. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. Gynecol Oncol. 2004;95 (3):686-690. doi:10.1016/j.ygyno.2004.09.005

47. Downs LS, Judson PL, Argenta PA, et al. A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma. Cancer. 2008;112 (2):331‑339. doi:10.1002/cncr.23164

48. Vandenput I, Amant F, Neven P, Berteloot P, Leunen K, Vergote I. Effectiveness of weekly topotecan in patients with recurrent epithelial ovarian cancer. Int J Gynecol Cancer. 2007;17 (1):83-87. doi:10.1111/j.1525-1438.2007.00789.x

49. Brown JV, Peters WA, Rettenmaier MA, et al. Three‑ consecutive‑ day topotecan is an active regimen for recurrent epithelial ovarian cancer. Gynecol Oncol. 2003;88 (2):136-140. doi:10.1016/S0090-8258(02)00021‑5

50. Hu CF, Ou YC, Fu HC, et al. The use of weekly topotecan in the treatment of heavily pretreated recurrent epithelial ovarian and primary peritoneal cancer: The Kaohsiung Chang Gung experience. Taiwan J Obstet Gynecol. 2015;54 (1):43-47. doi:10.1016/j.tjog.2014.11.005

51. Mitchell SK, Carson LF, Judson P, Downs LS. Efficacy and tolerability of lower‑ dose topotecan in recurrent ovarian cancer: a retrospective case review. Int J Gynecol Cancer. 2005;15 (5):793-798. doi:10.1111/j.1525-1438.2005.00138.x

52. Piura B, Rabinovich A. Topotecan in heavily pretreated patients with recurrent ovarian, peritoneal, and fallopian tube carcinoma. Int J Gynecol Cancer. 2005;15 (4):612‑ 617. doi:10.1111/j.1525-1438.2005.00116.x

53. O’Malley DM, Azodi M, Makkenchery A, et al. Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol. 2005;98 (2):242‑248. doi:10.1016/j.ygyno.2005.04.032

54. Anand A, Chan SY. The use of topotecan for relapsed ovarian cancer in accordance with the National Institute for Clinical Excellence guidance 2001: the Nottingham experience. Clin Oncol. 2004;16 (8):543-548. doi:10.1016/j.clon.2004.07.003

55. Bruchim I, Ben‑Harim Z, Piura E, Haran G, Fishman A. Analysis of two topotecan treatment schedules in patients with recurrent ovarian cancer. J Chemother. 2016;28 (2):129‑134. doi:10.1080/1120009X.2015.1115195

56. Le T, Hopkins L, Baines KA, Rambout L, Fung‑Kee‑Fung M. Prospective evaluation of weekly topotecan in recurrent platinum‑resistant epithelial ovarian cancer. Int J Gynecol Cancer. 2008;18 (3):428-431. doi:10.1111/j.1525‑1438.2007.01041.x

57. Karabulut B, Sezgin C, Terek MC, et al. Topotecan in Platinum‑Resistant Epithelial Ovarian Cancer. Chemotherapy. 2005;51 (6):347‑351. doi:10.1159/000088959

58. Rose PG, Gordon NH, Fusco N, et al. A Phase II and Pharmacokinetic Study of Weekly 72-h Topotecan Infusion in Patients with Platinum‑Resistant and Paclitaxel‑Resistant Ovarian Carcinoma. Gynecol Oncol. 2000;78 (2):228-234. doi:10.1006/gyno.2000.5844

59. Safra T, Menczer J, Bernstein R, et al. Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer. Gynecol Oncol. 2007;105 (1):205-210. doi:10.1016/j.ygyno.2006.11.017

60. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Phase 2 Evaluation of Topotecan Administered on a 3-Day Schedule in the Treatment of Platinum‑ and Paclitaxel‑Refractory Ovarian Cancer. Gynecol Oncol. 2000;79 (1):116-119. doi:10.1006/gyno.2000.5902

61. Poveda A, del Campo J, Ray‑Coquard I, et al. Phase II randomized study of PM01183 versus topotecan in patients with platinum‑resistant/ refractory advanced ovarian cancer. Ann Oncol. 2017;28 (6):1280-1287. doi:10.1093/annonc/mdx111|1281

62. Conteduca V, Gurioli G, Rossi L, et al. Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX‑ 4) as a salvage chemotherapy in heavily‑pretreated platinum‑resistant ovarian cancer. BMC Cancer. 2018;18 (1). doi:10.1186/s12885-0185180-1

63. Montazeri A, Culine S, Laguerre B, et al. Individual Adaptive Dosing of Topotecan in Ovarian Cancer.:7.

64. Rodriguez M, Rose PG. Improved Therapeutic Index of Lower Dose Topotecan Chemotherapy in Recurrent Ovarian Cancer. Gynecol Oncol. 2001;83 (2):257‑262. doi:10.1006/gyno.2001.6365

65. Gronlund B, Hansen HH, Høgdall C, Engelholm SA. Efficacy of low‑ dose topotecan in second‑line treatment for patients with epithelial ovarian carcinoma: Low‑Dose Topotecan and Ovarian Cancer. Cancer. 2002;95 (8):1656-1662. doi:10.1002/cncr.10838

66. Largillier R, Valenza B, Ferrero JM, et al. Haematological Evaluation of Weekly Therapy with Topotecan for the Treatment of Recurrent Ovarian Cancer Resistant to Platinum-Based Therapy. Oncology. 2007;73 (3-4):177‑184. doi:10.1159/000127384

67. Chekerov R, Hilpert F, Mahner S, et al. Sorafenib plus topotecan versus placebo plus topotecan for platinum‑resistant ovarian cancer (TRIAS): a multicentre, randomised, double‑blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2018;19 (9):1247‑1258. doi:10.1016/S1470-2045(18)30372‑3

68. Meier W, du Bois A, Reuss A, et al. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st‑line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol. 2009;114 (2):199‑205. doi:10.1016/j.ygyno.2009.04.026

69. Calcagno M, Bellati F, Palaia I, et al. Three‑Day Topotecan Schedule in Heavily Pretreated Recurrent Ovarian Cancer Patients. Int J Gynecol Cancer. 2009;19 (3):455-459. doi:10.1111/IGC.0b013e3181a1a7d2

70. Clarke‑Pearson DL, Van Le L, Iveson T, et al. Oral Topotecan as Single‑Agent Second‑Line Chemotherapy in Patients With Advanced Ovarian Cancer. J Clin Oncol. 2001;19 (19):3967‑3975. doi:10.1200/JCO.2001.19.19.3967

71. Abushahin F, Singh DK, Lurain JR, Grendys EC, Rademaker AW, Schink JC. Weekly topotecan for recurrent platinum resistant ovarian cancer. Gynecol Oncol. 2008;108 (1):53-57. doi:10.1016/j.ygyno.2007.08.062

72. Safra T, Berman T, Yachnin A, et al. Weekly Topotecan for Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma: Tolerability and Efficacy Study—The Israeli Experience. Int J Gynecol Cancer. 2013;23 (3):475-480. doi:10.1097/IGC.0b013e3182866944

73. Sehouli J, Stengel D, Harter P, et al. Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum‑Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North‑Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol. 2011;29 (2):242‑248. doi:10.1200/JCO.2009.27.8911

74. Kita T, Kikuchi Y, Takano M, et al. The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer. Gynecol Oncol. 2004;92 (3):813-818. doi:10.1016/j.ygyno.2003.12.002

75. Zanotti KM, Belinson JL, Kennedy AW, Webster KD, Markman M. Treatment of Relapsed Carcinoma of the Ovary with Single‑Agent Paclitaxel Following Exposure to Paclitaxel and Platinum Employed as Initial Therapy. Gynecol Oncol. 2000;79 (2):211‑215. doi:10.1006/gyno.2000.5958

76. Niwa Y, Nakanishi T, Kuzuya K, Nawa A, Mizutani S. Salvage treatment with docetaxel for recurrent epithelial ovarian cancer. Int J Clin Oncol. 2003;8 (6):343-347. doi:10.1007/s10147‑003-350-8

77. Ghamande S, Lele S, Marchetti D, Baker T, Odunsi K. Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer. Int J Gynecol Cancer. 2003;13 (2):142‑147. doi:10.1046/j.1525-1438.2003.13045.x

78. Linch M, Stavridi F, Hook J, Barbachano Y, Gore M, Kaye SB. Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer. Gynecol Oncol. 2008;109 (1):27‑32. doi:10.1016/j.ygyno.2008.01.007

79. Berkenblit A, Seiden MV, Matulonis UA, et al. A phase II trial of weekly docetaxel in patients with platinum‑resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Gynecol Oncol. 2004;95 (3):624-631. doi:10.1016/j.ygyno.2004.08.028

80. Markman M, Zanotti K, Webster K, Peterson G, Kulp B, Belinson J. Phase 2 trial of single agent docetaxel in platinum and paclitaxel‑refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum. Gynecol Oncol. 2003;91 (3):573-576. doi:10.1016/j.ygyno.2003.08.001

81. Le T, Hopkins L, Baines KA, Rambout L, Al Hayki M, Kee Fung MF. Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum‑resistant epithelial ovarian cancer. Gynecol Oncol. 2006;102 (1):49‑53. doi:10.1016/j.ygyno.2005.11.025

82. Katsumata N, Tsunematsu R, Tanaka K, et al. A phase II trial of docetaxel in platinum pre‑treated patients with advanced epithelial ovarian cancer: A Japanese Cooperative Study. Ann Oncol. 2000;11 (12):1531‑1536. doi:10.1023/A:1008337103708

83. McNeish IA, Ledermann JA, Webber L, et al. A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum‑resistant ovarian, fallopian tube or primary peritoneal cancer†. Ann Oncol. 2014;25 (10):1988-1995. doi:10.1093/annonc/mdu363

84. Pignata S, Lorusso D, Scambia G, et al. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum‑resistant or platinum‑refractory advanced ovarian cancer (MITO 11): a randomised, open‑label, phase 2 trial. Lancet Oncol. 2015;16 (5):561‑568. doi:10.1016/S1470-2045(15)70115-4

85. Coleman RL, Brady WE, McMeekin DS, et al. A phase II evaluation of nanoparticle, albumin‑bound (nab) paclitaxel in the treatment of recurrent or persistent platinum‑resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study. Gynecol Oncol. 2011;122 (1):111‑115. doi:10.1016/j.ygyno.2011.03.036

86. Markman M, Blessing J, Rubin SC, Connor J, Hanjani P, Waggoner S. Phase II trial of weekly paclitaxel (80 mg/m2 ) in platinum and paclitaxel‑resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study. Gynecol Oncol. 2006;101 (3):436-440. doi:10.1016/j.ygyno.2005.10.036

87. Coleman RL, Moon J, Sood AK, et al. Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. Eur J Cancer. 2014;50 (9):1638-1648. doi:10.1016/j.ejca.2014.03.005

88. Lortholary A, Largillier R, Weber B, et al. Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO). Ann Oncol. 2012;23 (2):346-352. doi:10.1093/annonc/mdr149

89. Rose PG, Blessing JA, Ball HG, et al. A phase II study of docetaxel in paclitaxel‑resistant ovarian and peritoneal carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2003;88 (2):130-135. doi:10.1016/S0090-8258(02)00091‑4

90. Liu JF, Ray‑ Coquard I, Selle F, et al. Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum‑Resistant or-Refractory Ovarian Cancer. J Clin Oncol. 2016;34 (36):4345-4353. doi:10.1200/JCO.2016.67.1891

91. Omura GA, Brady MF, Look KY, et al. Phase III Trial of Paclitaxel at Two Dose Levels, the Higher Dose Accompanied by Filgrastim at Two Dose Levels in Platinum‑Pretreated Epithelial Ovarian Cancer: An Intergroup Study. J Clin Oncol. 2003;21 (15):2843-2848. doi:10.1200/JCO.2003.10.082

92. Rumyantsev A, Tyulyandina A, Fedyanin M, et al. Efficacy of platinum‑based chemotherapy in platinum‑resistant ovarian cancer: A systematic review with pooled analysis of outcomes. J Clin Oncol. 2020;38 (15_suppl): e18076-e18076. doi:10.1200/JCO.2020.38.15_suppl.e18076

93. Rose PG, Tian C, Bookman MA. Assessment of tumor response as a surrogate endpoint of survival in recurrent/ platinum‑resistant ovarian carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 2010;117 (2):324-329. doi:10.1016/j.ygyno.2010.01.040

94. Siddiqui MK, Tyczynski J, Pahwa A, Fernandes AW. Objective response rate is a possible surrogate endpoint for survival in patients with advanced, recurrent ovarian cancer. Gynecol Oncol. 2017;146 (1):44-51. doi:10.1016/j.ygyno.2017.03.515

95. Blackledge G, Lawton F, Redman C, Kelly K. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer. 1989;59 (4):650-653. doi:10.1038/bjc.1989.132

96. Alsop K, Fereday S, Meldrum C, et al. BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30 (21):2654-2663. doi:10.1200/JCO.2011.39.8545

97. Hanker LC, Loibl S, Burchardi N, et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum‑based therapy. Ann Oncol. 2012;23(10):2605-2612. doi:10.1093/annonc/mds203